Table.

Patient characteristics

		Wave 1 (March 1, to May 31, 2020)	Wave 2 (Nov 1, 2020, to Jan 19, 2021)
Number of patients		20	60
Age, years		1 (0·1–11)	6 (0·7–13)
Sex
	Male	9 (45%)	40 (67%)
	Female	11 (55%)	20 (33%)
Comorbidities		7 (35%)	25 (42%)
BAME ethnicity		6 (46%; n=13)	20 (42%; n=48)
IMD score		28·3 (11·6–36·1)	20·5 (14·7–32·2)
Clinical severity (modified WHO definition)*
	Critical disease	4 (20%)	2 (3%)
	Severe disease	1 (5%)	3 (5%)
	Moderate disease	5 (25%)	8 (13%)
	Mild disease	8 (40%)	27 (45%)
	Asymptomatic or incidental findings	2 (10%)	20 (33%)
Management
	Oxygen	7 (35%)	5 (8%)
	Non-invasive ventilation	3 (15%)	2 (3%)
	Invasive ventilation	4 (20%)	1 (2%)
	Remdesivir	1 (5%)	4 (7%)
	Steroids (low dose)	0	5 (8%)
	Monoclonal antibodies (casirivimab and imdevimab)	0	1 (2%)

Data are n, n (%), or median (IQR), unless otherwise specified. BAME=Black, Asian, and minority ethnicity. IMD=Index of Multiple Deprivation score.

^*For the modified WHO definition see the appendix).